ASX

Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Retrieved on: 
Tuesday, March 19, 2024
Urinary tract infection, Global health, Patient, ASX, RCE, Infection, Pyelonephritis, Pharmaceutical industry

“Completing dosing of our latest cohort marks another milestone in our journey toward advancing R327 as a potential frontline treatment for patients with UTIs or urosepsis,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “Completing dosing of our latest cohort marks another milestone in our journey toward advancing R327 as a potential frontline treatment for patients with UTIs or urosepsis,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • “We are dedicated to delivering impactful solutions to combat infectious diseases and improve global health outcomes.”
    An Independent Safety Committee will now review and evaluate the comprehensive data from the 4-subject cohort.
  • Data from this trial is expected to pave the way for a Phase II trial to establish the potential of R327 as a frontline treatment for patients with UTIs or urosepsis.
  • The administration of antibiotics via rapid intravenous infusions is a proven safe and effective method of administration, impacting patient treatment, wait times, and nursing workloads globally.

QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy

Retrieved on: 
Monday, March 18, 2024
Radiation, CE, Artificial intelligence, ASX, European, TLX, FDA, Medical imaging

QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.

Key Points: 
  • QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.
  • Telix intends to integrate the QDOSE® platform into its therapeutic radiopharmaceutical programs and clinical collaborations to enable the development of personalized treatment regimens.
  • Personalized radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimizing treatment response while reducing effects on normal healthy organs and optimizing the use of isotope supply chains.
  • Rapid, reliable and personalized dosimetry is becoming an increasingly important future direction of cancer care and regulatory authorities now expect to see dosimetry analysis.

American Rare Earths’ Scoping Study confirms low-cost, scalable world-class REE project

Retrieved on: 
Monday, March 18, 2024
Tetra, Silica gel, Temperature, Mining, Target, ARR, Mineral Resources Limited, Newmont, Filtration, ESG, ASARCO, Thorium, Economic development, ASX, Public expenditure, Environmental quality, Measurement, Molycorp, Stantec, UP, Base case, Society, Competent person, REE, Mineral, Tetra Tech, Engineering, BNSF, IRR, Chemical engineering, NPV, Resource, Allanite, Cowboy, Goldcorp, Metamictisation, Work, Rare-earth element

We note these prices are not sustainable given current prices are at the cash costs of China Northern Rare Earths.

Key Points: 
  • We note these prices are not sustainable given current prices are at the cash costs of China Northern Rare Earths.
  • The inferred Mineral Resource is not the determining factor in determining the viability of the Halleck Creek Rare Earths project.
  • American Rare Earths (ASX: ARR | OTCQX: ARRNF and AMRRY) owns the Halleck Creek, WY and La Paz, AZ rare earth deposits.
  • The Company’s flagship project at Halleck Creek, WY, has the potential to become the largest and most sustainable rare earth projects in North America.

Weebit Nano to demo its ReRAM technology on GlobalFoundries’ 22FDX® platform

Retrieved on: 
Monday, March 18, 2024
Physics, Resistive random-access memory, Embedded, ASX, HW, HOD, Engineering, Silicon, Computer data storage

HOD HASHARON, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- Weebit Nano Limited (ASX:WBT), a leading developer of advanced memory technologies for the global semiconductor industry, will showcase a live demo of Resistive Random-Access Memory (ReRAM) technology implemented in GlobalFoundries’ 22FDX® platform.

Key Points: 
  • HOD HASHARON, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- Weebit Nano Limited (ASX:WBT), a leading developer of advanced memory technologies for the global semiconductor industry, will showcase a live demo of Resistive Random-Access Memory (ReRAM) technology implemented in GlobalFoundries’ 22FDX® platform.
  • The demo confirms the capability of ReRAM in this advanced geometry – a process node where embedded flash is unable to scale.
  • It also highlights some of the numerous capabilities of Weebit ReRAM, including ultra-low power consumption, fast programming time and byte addressability.
  • The 8Mb Weebit ReRAM demo chip in 22nm has the largest memory capacity of any Weebit module to-date and is implemented in the most advanced process so far.

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

Retrieved on: 
Friday, March 15, 2024
Health, Sleep apnea, Conditional sentence, Obesity, Exercise, RMD, ResMed, Somnolence, SAN, Insomnia, Social media, Sleep, ASX, News, Female, Irritation, Woman, Periodic breathing, COPD, Nursing

More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality.

Key Points: 
  • More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality.
  • SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and other chronic diseases, today announced the results of its 2024 Global Sleep Survey in conjunction with World Sleep Day (March 15), shedding light on the critical sleep challenges faced by people around the world.
  • To learn more about ResMed’s 2024 Global Sleep Survey or for help identifying if you have symptoms that could indicate poor sleep health, visit https://www.resmed.com/sleepassessment .
  • The 2024 ResMed Global Sleep Survey included a total of 36,000 respondents across 17 markets including Australia, Brazil, China, France, Germany, Hong Kong, India, Ireland, Japan, Korea, Mexico, New Zealand, Singapore, Taiwan, Thailand, UK and USA, between December 2023 and January 2024.

Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Retrieved on: 
Thursday, March 14, 2024
Phase, Urinary tract infection, Patient, Pyelonephritis, ASX, RCE, Recce, Pharmaceutical industry

The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming days

Key Points: 
  • The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming days
    RECCE® 327 now tested at four infusion times, achieving these timestamps in line with intended future regulatory submissions
    SYDNEY, Australia, March 14, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it dosed the next cohort of healthy subjects at 3,000mg within a fast infusion rate of 20-minutes in a Phase I/II trial evaluating its lead candidate, RECCE® 327 (R327).
  • “We're pleased to continue advancing the clinical profile of R327, which has demonstrated safe and efficacious potential against a broad range of antibiotic-resistant pathogens across multiple studies,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • The Company has established that the dose of 3,000mg, administered at varying infusion times between 15 and 60 minutes, has been proven safe in participants.
  • The efficacy of R327 via intravenous administration will be made available at the completion of the Phase I/II trial in line with the study protocol.

Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Safety, Annual general meeting, Poster, ASX, RCE, Society, Intravenous therapy

SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a poster presentation of data from a Phase 1 study evaluating the safety of its lead asset, RECCE® 327, at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado.

Key Points: 
  • SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a poster presentation of data from a Phase 1 study evaluating the safety of its lead asset, RECCE® 327, at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado.
  • Details for the presentation are as follows:
    Title: FIH Study of Intravenous RECCE 327: A Novel, Broad Spectrum, Synthetic Anti-Infective
    A copy of the poster will be available on Recce’s website after the conclusion of the conference.

Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance

Retrieved on: 
Tuesday, March 12, 2024
Government, Infection, Acceleration, Partnership, Research, ASX, RCE, Recce

Recce received $11.17 million in non-dilutive cash, reflecting R&D rebate credits for FY23/24, in addition to future anticipated R&D applicable expenditure for FY25.

Key Points: 
  • Recce received $11.17 million in non-dilutive cash, reflecting R&D rebate credits for FY23/24, in addition to future anticipated R&D applicable expenditure for FY25.
  • This enables the Company to leverage its R&D expenditure benefits of the past, present, and future R&D applicable expenditure on a here-today basis, as achieved by this agreement.
  • “Securing this advanced funding from Endpoints is a testament to the strength of Recce’s scientific platform and the potential of our pipeline,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Any surplus to R&D rebates, including around an imminent R&D rebate to FY23, is always that of Recce’s.

SSR Mining Provides Update on Çöpler Incident

Retrieved on: 
Friday, April 5, 2024
Mining, Minerals, Natural Resources, SSR, SSRM, EDGAR, Family, ASX, News, Annual report

SSR Mining Inc. (Nasdaq/TSX: SSRM; ASX: SSR) (“SSR Mining” or the “Company”) provides an update on the ongoing recovery efforts at the Çöpler mine in Türkiye.

Key Points: 
  • SSR Mining Inc. (Nasdaq/TSX: SSRM; ASX: SSR) (“SSR Mining” or the “Company”) provides an update on the ongoing recovery efforts at the Çöpler mine in Türkiye.
  • Since the February 13, 2024 incident, the priority at Çöpler has been the recovery of our nine missing colleagues.
  • Further updates on the incident will continue to be provided through press releases and updates to the Company’s website.
  • Other than as required by law, we do not intend, and undertake no obligation to update any forward-looking information to reflect, among other things, new information or future events.

Orion Undertakes A$593 Million Sale of Capstone CDIs on the ASX

Retrieved on: 
Friday, April 5, 2024
Natural Resources, Other Natural Resources, Mining, Minerals, Indian stock exchange, CSC, Pacific Ocean, CDI, CHESS, Macquarie Group, ASX, Sale, Regulation, News, CS, Orion, Prospectus, TSX, BTA, Pacific Time Zone, RBC Capital Markets, Security (finance)

The Secondary Offering is expected to close on or about April 9, 2024 (Pacific Time).

Key Points: 
  • The Secondary Offering is expected to close on or about April 9, 2024 (Pacific Time).
  • The net proceeds of the Secondary Offering will be paid directly to the Selling Shareholders.
  • The Selling Shareholders currently hold an aggregate of 152,936,179 Common Shares1, representing approximately 20.3% of the Company’s issued and outstanding Common Shares.
  • The Prospectus Supplement will be filed on the SEDAR+ website maintained by the Canadian Securities Administrators at www.sedarplus.ca on or before April 8, 2024 and released on the ASX.